Preemptive Medicine for Dementia

Medical Frontiers

28m 00s
Broadcast on July 19, 2021 Available until July 19, 2022

In June 2021, aducanumab, the first drug to target the cause of Alzheimer's disease, was approved in the US, making headlines worldwide. We look at the results of clinical trials involving over 3,000 participants from 20 countries, differences between the drug and conventional treatments, and the drug's limitations. We also focus on a preceding condition called mild cognitive impairment, or MCI. Japanese researchers developed a way to reverse cognitive decline in those with MCI, and a test to see whether someone is developing it.

Program Outline